Allergan (AGN) Slips Lower on FDA Generic Restasis Discussion
Tweet
Share
E-mailGet Alerts AGN Hot Sheet
Join SI Premium – FREE
Allergan (NYSE: AGN) is lower on Friday's session following a new FDA document which discusses generic cyclosporine ophthalmic emulsion (generic Restasis).
To read the full document (in pdf form), click here.
Shares pf Allergan are down 5.4 percent.
To read the full document (in pdf form), click here.
Shares pf Allergan are down 5.4 percent.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Dollar Tree (DLTR) falls 5.6% after Director filed notice to sell $133.1M worth of shares
- Omeros stock tumbles after EU panel rejects Yartemlea
- Regenxbio shares jump after FDA agrees to reverse drug rejection
Create E-mail Alert Related Categories
FDA, Insiders' Blog, Momentum MoversSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
